Unlocking Answers: Why Genetic Testing Matters in AML Care image

Unlocking Answers: Why Genetic Testing Matters in AML Care

Mar 05, 2025
12:30PM - 01:30PM EST
Online Event
Overview

Join us for an insightful session with Dr. Harry Erba, a renowned expert in AML care, as we uncover the importance of genetic testing in managing AML. Learn how understanding your genetic profile can influence treatment options and improve outcomes. Dr. Erba will simplify complex concepts, empowering you to make informed decisions about your care. Don’t miss this opportunity to gain valuable knowledge and ask your questions directly to one of the leading voices in AML research and treatment.

Agenda
12:30 PM
Introduction
Marilu N Flores

Marilu introduces the agenda for the event and featured speaker Harry P. Erba, MD, PhD

12:35 PM
Presentation
Harry P. Erba, MD, PhD

Dr. Erba talks about genetic testing for AML

1:05 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Marilu N Flores

Marilu N Flores

In-Person Event Operations Manager, HealthTree Foundation

Patient Education
Healthtree contact Harry P. Erba, MD, PhD

Harry P. Erba, MD, PhD

Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapy Director, Leukemia Program, Duke University, Durham, NC Chair, SWOG Leukemia Committee Dr Erba is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy at Duke University. He serves as the Director of the Leukemia Program. Dr Erba graduated from Yale University with a Bachelor of Science degree in Biology. He earned his medical degree and doctor of philosophy degree in Biophysics from Stanford University School of Medicine in California. He completed his internship, residency and fellowship at Brigham and Women’s Hospital. He has been a clinical investigator for myeloid neoplasms at the University of Michigan (1996-2012), University of Alabama at Birmingham (2012-2018), and Duke University since 2018. He has served as the Chair of the SWOG Leukemia Committee since 2012, member of the NCI Leukemia Steering Committee since 2012, and the Co-Chair of the Senior Scientific Council of the NCI-sponsored MyeloMATCH precision medicine initiative since 2019.